Innovent Biologics, Inc. (IVBXF) Financials

IVBXF Assets vs Liabilities
DateAssetsLiabilities
Dec. 31, 2025 5.3 billion 2.5 billion
June 30, 2025 3.3 billion 1.3 billion
Dec. 31, 2024 3.0 billion 1.2 billion
June 30, 2024 2.8 billion 1.1 billion

IVBXF Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
Dec. 31, 2025 ? ?
June 30, 2025 29.5 million 47.8 million
Dec. 31, 2024 169.4 million 35.5 million
June 30, 2024 -125.9 million 41.0 million

IVBXF Net Income

No data available :(

IVBXF Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
Dec. 31, 2025 2.6 billion 284.5 million 3.7 million
June 30, 2025 1.3 billion 315.9 million 1.1 million
Dec. 31, 2024 1.1 billion 330.5 million 1.9 million
June 30, 2024 1.2 billion 312.5 million 19.7 million

IVBXF Shares Outstanding

No data available :(

IVBXF Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
Dec. 31, 2025 - 227.1 million 537.3 million -
June 30, 2025 14.3 million 140.8 million 393.2 million 331.5 million
Dec. 31, 2024 36.5 million 175.6 million 395.4 million 338.1 million
June 30, 2024 96.3 million 192.6 million 302.6 million 258.6 million

IVBXF Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
Dec. 31, 2025 996.3 million 129.7 million
June 30, 2025 831.0 million 188.9 million
Dec. 31, 2024 749.3 million 180.5 million
June 30, 2024 543.9 million 150.6 million

IVBXF

Price: $9.79

52 week price:
9.01
15.12

Earnings Per Share: 0.07 USD

P/E Ratio: 167.14

Exchange: PNK

Sector: Healthcare

Industry: Biotechnology

Market Capitalization: 17.5 billion

Links: